Cargando…

Immune Responses against SARS-CoV-2—Questions and Experiences

Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangge, Harald, Kneihsl, Markus, Schnedl, Wolfgang, Sendlhofer, Gerald, Curcio, Francesco, Domenis, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533170/
https://www.ncbi.nlm.nih.gov/pubmed/34680460
http://dx.doi.org/10.3390/biomedicines9101342
_version_ 1784587247072313344
author Mangge, Harald
Kneihsl, Markus
Schnedl, Wolfgang
Sendlhofer, Gerald
Curcio, Francesco
Domenis, Rossana
author_facet Mangge, Harald
Kneihsl, Markus
Schnedl, Wolfgang
Sendlhofer, Gerald
Curcio, Francesco
Domenis, Rossana
author_sort Mangge, Harald
collection PubMed
description Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, and they do not pass the virus on to anyone else (“sterilizing” immunity). Others produce antibodies and do not get COVID-19 but transmit the virus to others (“protective” immunity). Some people get sick but recover. A varying percentage develops respiratory failure, systemic symptoms, clotting disorders, cytokine storms, or multi-organ failure; they subsequently decease. Some develop long COVID, a new pathologic entity similar to fatigue syndrome or autoimmunity. In reality, COVID-19 is considered more of a systemic immune–vascular disease than a pulmonic disease, involving many tissues and the central nervous system. To fully comprehend the complex clinical manifestations, a profound understanding of the immune responses to SARS-CoV-2 is a good way to improve clinical management of COVID-19. Although neutralizing antibodies are an established approach to recognize an immune status, cellular immunity plays at least an equivalent or an even more important role. However, reliable methods to estimate the SARS-CoV-2-specific T cell capacity are not available for clinical routines. This deficit is important because an unknown percentage of people may exist with good memory T cell responsibility but a low number of or completely lacking peripheral antibodies against SARS-CoV-2. Apart from natural immune responses, vaccination against SARS-CoV-2 turned out to be very effective and much safer than naturally acquired immunity. Nevertheless, besides unwanted side effects of the currently available vector and mRNA preparations, concerns remain whether these vaccines will be strong enough to defeat the pandemic. Altogether, herein we discuss important questions, and try to give answers based on the current knowledge and preliminary data from our laboratories.
format Online
Article
Text
id pubmed-8533170
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85331702021-10-23 Immune Responses against SARS-CoV-2—Questions and Experiences Mangge, Harald Kneihsl, Markus Schnedl, Wolfgang Sendlhofer, Gerald Curcio, Francesco Domenis, Rossana Biomedicines Review Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, and they do not pass the virus on to anyone else (“sterilizing” immunity). Others produce antibodies and do not get COVID-19 but transmit the virus to others (“protective” immunity). Some people get sick but recover. A varying percentage develops respiratory failure, systemic symptoms, clotting disorders, cytokine storms, or multi-organ failure; they subsequently decease. Some develop long COVID, a new pathologic entity similar to fatigue syndrome or autoimmunity. In reality, COVID-19 is considered more of a systemic immune–vascular disease than a pulmonic disease, involving many tissues and the central nervous system. To fully comprehend the complex clinical manifestations, a profound understanding of the immune responses to SARS-CoV-2 is a good way to improve clinical management of COVID-19. Although neutralizing antibodies are an established approach to recognize an immune status, cellular immunity plays at least an equivalent or an even more important role. However, reliable methods to estimate the SARS-CoV-2-specific T cell capacity are not available for clinical routines. This deficit is important because an unknown percentage of people may exist with good memory T cell responsibility but a low number of or completely lacking peripheral antibodies against SARS-CoV-2. Apart from natural immune responses, vaccination against SARS-CoV-2 turned out to be very effective and much safer than naturally acquired immunity. Nevertheless, besides unwanted side effects of the currently available vector and mRNA preparations, concerns remain whether these vaccines will be strong enough to defeat the pandemic. Altogether, herein we discuss important questions, and try to give answers based on the current knowledge and preliminary data from our laboratories. MDPI 2021-09-28 /pmc/articles/PMC8533170/ /pubmed/34680460 http://dx.doi.org/10.3390/biomedicines9101342 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mangge, Harald
Kneihsl, Markus
Schnedl, Wolfgang
Sendlhofer, Gerald
Curcio, Francesco
Domenis, Rossana
Immune Responses against SARS-CoV-2—Questions and Experiences
title Immune Responses against SARS-CoV-2—Questions and Experiences
title_full Immune Responses against SARS-CoV-2—Questions and Experiences
title_fullStr Immune Responses against SARS-CoV-2—Questions and Experiences
title_full_unstemmed Immune Responses against SARS-CoV-2—Questions and Experiences
title_short Immune Responses against SARS-CoV-2—Questions and Experiences
title_sort immune responses against sars-cov-2—questions and experiences
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533170/
https://www.ncbi.nlm.nih.gov/pubmed/34680460
http://dx.doi.org/10.3390/biomedicines9101342
work_keys_str_mv AT manggeharald immuneresponsesagainstsarscov2questionsandexperiences
AT kneihslmarkus immuneresponsesagainstsarscov2questionsandexperiences
AT schnedlwolfgang immuneresponsesagainstsarscov2questionsandexperiences
AT sendlhofergerald immuneresponsesagainstsarscov2questionsandexperiences
AT curciofrancesco immuneresponsesagainstsarscov2questionsandexperiences
AT domenisrossana immuneresponsesagainstsarscov2questionsandexperiences